Figure1: Top) Simplified diagram showing the common steps
during drug development from drug discovery to clinical trials.
After discovery or synthesis of a new potential antineoplastic
drug, the compound undergoes preclinical research where is
tested in cell free systems as well as in vivo in cell lines and
animal models. Promising candidates that pass the preclinical
stage are approved for clinical trials and few reach the “clinical
use” stage. At the “clinical trial”/”drug use” transition the presence of a “bottleneck” limits the success rate. The success rate
(defined as the number of drugs that reach the stage of clinical
use divided by the number of drugs that enter the number of
drugs clinical trial; nCU/nCT) , value between 0-1, is an indication
of the cost/benefit of the program.
B) Proposed outcome of drug development by introducing a“preclinical bottleneck” by using the RC0 as endpoint parameter during preclinical research. The presence of the “preclinical bottleneck” will reduce the number of cells entering the “clinical trial stage” and might increase the success rate improving the cost/benefit.
B) Proposed outcome of drug development by introducing a“preclinical bottleneck” by using the RC0 as endpoint parameter during preclinical research. The presence of the “preclinical bottleneck” will reduce the number of cells entering the “clinical trial stage” and might increase the success rate improving the cost/benefit.